In addition, a more recent survey including 67 immune and inflammation markers between 301 patients with non-Hodgkin lymphoma diagnosed 5+ years after blood collection showed that higher serum CXCL13 level predicts future occurrences of DLBCL (7). This evidence concerns the gene CXCL13 and diffuse large B-cell lymphoma.